The new oral anticoagulants are announced as an important therapeutic revolution, particularly after their approval by authorities for stroke prevention in atrial fibrillation. However, the pharmacology of these new drugs is not homogeneous. In this review, we summarize the main pharmacological characteristics of the new direct anti-Xa and anti-IIa agents.
Keywords: anticoagulant; apixaban; dabigatran; edoxaban; heparin; pharmacology; rivaroxaban.
© 2014 Société Française de Pharmacologie et de Thérapeutique.